Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opicinumab - Biogen

Drug Profile

Opicinumab - Biogen

Alternative Names: Anti-LINGO 1; Anti-LINGO-1 antibody; BIIB-033

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Dyax
  • Developer Biogen
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Neuropsychotherapeutics
  • Mechanism of Action Cell differentiation stimulants; LINGO 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Optic neuritis

Most Recent Events

  • 13 Oct 2021 Safety and efficacy data from the phase II AFFINITY trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)
  • 01 Mar 2021 Biogen terminates the phase II AFFINITY trial for Multiple sclerosis (Adjunctive treatment) as it fails to achieve its primary and secondary endpoints in Australia, Belgium, Canada, Czech Republic, France, Germany, Switzerland, Netherlands, Poland, Spain, Hungary, Italy, United Kingdom (IV) (NCT03222973)
  • 21 Oct 2020 Discontinued - Phase-II for Multiple sclerosis in European Union, USA, United Kingdom, Canada (IV), and Multiple sclerosis (Adjunctive treatment) in European Union, USA, Australia (IV) in October 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top